Please login to the form below

Not currently logged in
Email:
Password:

galcanezumab

This page shows the latest galcanezumab news and features for those working in and with pharma, biotech and healthcare.

Amgen and Novartis migraine drug hits the mark again

Amgen and Novartis migraine drug hits the mark again

other CGRP drugs in development, a group which includes Eli Lilly's galcanezumab, Teva's fremanezumab and Alder's eptinezumab.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics